434 related articles for article (PubMed ID: 16472877)
1. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
2. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
3. In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.
Javanbakht H; Ptak RG; Chow E; Yan JM; Russell JD; Mankowski MK; Hogan PA; Hogg JH; Vora H; Hang JQ; Li Y; Su G; Paul A; Cammack N; Klumpp K; Heilek G
Antiviral Res; 2010 May; 86(2):212-9. PubMed ID: 20219553
[TBL] [Abstract][Full Text] [Related]
4. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
5. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
6. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
7. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
Parkin NT; Gupta S; Chappey C; Petropoulos CJ
Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
9. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
11. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
[TBL] [Abstract][Full Text] [Related]
12. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
13. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
14. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
15. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
16. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
[TBL] [Abstract][Full Text] [Related]
17. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
18. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.
Berkhout B; Back NK; de Ronde A; Jurriaans S; Bakker M; Parkin NT; van der Hoek L
AIDS; 2006 Jul; 20(11):1515-20. PubMed ID: 16847406
[TBL] [Abstract][Full Text] [Related]
19. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
